Joseph P. Hagan, Senior VP, Corporate Development at Orexigen Therapeutics, Inc. (OREX), bought 5,000 shares at $4.69 ($23K) on 2014-09-15, disclosed to the SEC on 2014-09-15.
Open-market purchase of $23k OREX by Senior VP, Corporate Development. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| Filing → |
| RGLS | SELL | 2024-01-18 | $17K | — | Filing → |
| AUPH | SELL | 2023-05-23 | $3K | — | Filing → |
| RGLS | BUY | 2022-01-26 | $22K | — | Filing → |